Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Nanoparticle-Based Drug Formulation for Enhancing Nose-to-Brain Delivery
share announcement

Nanoparticle-Based Drug Formulation for Enhancing Nose-to-Brain Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1236

Special Issue Editors

Prof. Dr. Jagdish Singh

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Health Professions, North Dakota State University, Fargo, ND 58108-6050, USA
Interests: nanoparticle; targeted delivery; brain-drug delivery; intranasal; nanomicelles; liposomes
Special Issues, Collections and Topics in MDPI journals
Dr. Richard Nii Lante Lamptey

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA
Interests: brain-targeted; neurogenic disorders; intranasal; nose-to-brain; blood pressure; targeted delivery; nanoparticles; liposomes

Special Issue Information

Dear Colleagues,

Nanoparticle-based drug formulations offer a novel and promising approach for direct nose-to-brain delivery, bypassing the blood–brain barrier (BBB), which is a significant obstacle in treating central nervous system (CNS) disorders. This non-invasive method allows for targeted delivery of therapeutics, reducing systemic side effects and improving drug bioavailability in the brain. With advancements in nanotechnology, nanoparticles can be tailored to enhance the absorption, stability, and controlled release of drugs. This Special Issue aims to explore the latest innovations, challenges, and clinical applications of nanoparticles in nose-to-brain drug delivery, highlighting its potential for treating neurodegenerative diseases, brain tumors, and psychiatric disorders.

Prof. Dr. Jagdish Singh
Dr. Richard Nii Lante Lamptey
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • nose-to-brain drug delivery
  • blood–brain barrier (BBB)
  • central nervous system (CNS)
  • neurodegenerative diseases
  • targeted therapeutics
  • non-invasive delivery
  • intranasal administration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

44 pages, 1441 KB  
Review
Nanoparticle-Mediated Nose-to-Brain Delivery for Ischemic Stroke Therapy: Preclinical Insights
by Joonhyuck Park and Tae-Ryong Riew
Pharmaceutics 2025, 17(11), 1447; https://doi.org/10.3390/pharmaceutics17111447 (registering DOI) - 9 Nov 2025
Abstract
Ischemic stroke remains a major cause of mortality and long-term disability, yet current therapeutic strategies are largely limited to reperfusion approaches such as intravenous thrombolysis and thrombectomy, which are constrained by narrow treatment windows and the risk of complications. Moreover, the blood–brain barrier [...] Read more.
Ischemic stroke remains a major cause of mortality and long-term disability, yet current therapeutic strategies are largely limited to reperfusion approaches such as intravenous thrombolysis and thrombectomy, which are constrained by narrow treatment windows and the risk of complications. Moreover, the blood–brain barrier (BBB) severely restricts drug penetration into the injured brain, limiting the translation of promising neuroprotective agents into clinical success. Intranasal (IN) delivery has emerged as a compelling alternative route that bypasses the BBB and enables rapid access to the central nervous system through olfactory, trigeminal, and perivascular pathways. This narrative review highlights recent advances in preclinical research on IN therapeutics for ischemic stroke, ranging from small molecules and biologics to nucleic acids and cell-based therapies. Particular emphasis is placed on the application of nanotechnology, including extracellular vesicles, liposomes, and inorganic nanoparticles, which enhance drug stability, targeting, and bioavailability. Studies demonstrate that IN delivery of growth factors, cytokines, and engineered stem cells can promote neurogenesis, angiogenesis, white matter repair, and functional recovery, while nanocarriers further expand the therapeutic potential. Overall, intranasal delivery represents a promising and non-invasive strategy to overcome the limitations of conventional stroke therapies, offering new avenues for neuroprotection and regeneration that warrant further investigation toward clinical translation. Full article
(This article belongs to the Special Issue Nanoparticle-Based Drug Formulation for Enhancing Nose-to-Brain Delivery)
29 pages, 2911 KB  
Review
Polymeric Nanocarrier-Based Drug Formulations for Enhancing Nose-to-Brain Delivery
by Tobeka Naki, Sijongesonke Peter and Sibusiso Alven
Pharmaceutics 2025, 17(10), 1242; https://doi.org/10.3390/pharmaceutics17101242 - 23 Sep 2025
Viewed by 729
Abstract
Neurological-related diseases are among the most debilitating and difficult to manage. Many possible pharmacological treatments for neurological diseases struggle to cross the blood–brain barrier (BBB) to achieve concentrations that can produce a therapeutic benefit. This is primarily because of the existence of the [...] Read more.
Neurological-related diseases are among the most debilitating and difficult to manage. Many possible pharmacological treatments for neurological diseases struggle to cross the blood–brain barrier (BBB) to achieve concentrations that can produce a therapeutic benefit. This is primarily because of the existence of the BBB, which poses significant hurdles for both therapeutic and diagnostic efforts by restricting the entry of most medications. Nasal-to-brain drug transportation has surfaced as an encouraging approach to tackle the difficulties linked with conventional drug administration techniques for neurological disorders. In response, innovative methods for improving drug delivery focus on breaking down the BBB via physical techniques, including optical and photothermal therapy, electrical stimulation, and acoustic or mechanical stimulation. Nanocarriers represent a promising approach for facilitating nasal systemic and brain delivery of active compounds. Hence, the achievement of therapeutically relevant concentrations of exogenous molecules within the body is significantly contingent upon the nanocarriers’ capability to surpass biological barriers. Polymers in nanocarrier formulations can result in significantly enhanced nose-to-brain drug delivery by protecting drugs from premature biodegradation, increasing permeability, improving mucoadhesion, and targeting specific cells in the brain. Polymeric nanocarriers are frequently functionalized with cell-penetrating peptides to further improve the specificity of the loaded therapeutic molecules. This review focuses on the use of nanocarrier-based therapeutic agents to enhance the efficacy of nose-to-brain delivery systems. Full article
(This article belongs to the Special Issue Nanoparticle-Based Drug Formulation for Enhancing Nose-to-Brain Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop